Redhill Biopharma
RDHL
42 hedge funds and large institutions have $39.4M invested in Redhill Biopharma in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
61% more call options, than puts
Call options by funds: $252K | Put options by funds: $157K
14% more funds holding
Funds holding: 37 → 42 (+5)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% less ownership
Funds ownership: 0% → 0% (-0%)
31% less capital invested
Capital invested by funds: $56.8M → $39.4M (-$17.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$4.52M |
| 2 |
GS
Gagnon Securities
New York
|
+$722K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$652K |
| 4 |
State Street
Boston,
Massachusetts
|
+$511K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$166K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$15.6M |
| 2 |
II
Ibex Investors
Denver,
Colorado
|
-$665K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$586K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$174K |
| 5 |
Millennium Management
New York
|
-$118K |
RDHL Hedge Fund Activity: Q4 2019 in Review
42 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2019, worth a combined $39.4M — down 31% from $56.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RDHL positions and 6 closed out — a net gain of 5 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Disciplined Growth Investors, adding an estimated $4.52M. The largest seller was 683 Capital Management, cutting an estimated $15.6M.
- 42 institutional investors held Redhill Biopharma (RDHL) as of Q4 2019, up from 37 in Q3 2019.
- Funds reported $39.4M of Redhill Biopharma stock for Q4 2019, down 31% quarter-over-quarter.
- 11 funds opened new Redhill Biopharma positions in Q4 2019 and 6 closed out, a net change of +5 holders.
- The largest Redhill Biopharma buyer in Q4 2019 was Disciplined Growth Investors, an estimated $4.52M added.
- The largest Redhill Biopharma seller in Q4 2019 was 683 Capital Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2019.